R&D | November 07, 2025
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus
Collaboration aims to deliver rapid, lab-quality testing to communities worldwide – making precision health more accessible
Bayer remains a key partner in Ginkgo Bioworks’ growing agricultural biologicals platform
Speakers are: Dr. Alok Khullar, Senior Technology Leader, Pidilite Industries; Dr. Kamlesh Pai Fondekar, Head - R&D, Godrej Agrovet; Dr. Hiten Mehta, Head - R&D (Chlor-Alkali), Aditya Birla Chemicals; Dr. Anil Kumar Soni, Head - Application Development, R&D, Clariant Chemicals India; Dr. Rupak Paul, Deputy General Manager – Formulation, Rallis India; Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals; and Pravin Prashant, Executive Editor, Indian Pharma Post
This integrated center combines development, testing, evaluation, and industry-academia-research collaboration
From material selection to cooling tower management, every small decision affects long-term equipment reliability
The company has introduced an innovative Dual Release Proton Pump Inhibitor (PPI) tablet, a next-generation therapy for patients suffering from moderate to severe or treatment resistant gastroesophageal reflux disease
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
